sponsored
PatientsVille.com Logo

PatientsVille

Amias Medical Research Studies

Up-to-date List of Amias Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Amias Medical Research Studies

Rank Status Study
1 Not yet recruiting CKD-330 Drug-Drug Interaction Study (Candesartan)
Condition: Hypertension
Interventions: Drug: Candesartan 32mg;   Drug: Candesartan 32mg/Amlodipine 10mg
Outcome Measures: AUCτ,ss of Candesartan;   Cmax,ss of Candesartan;   Tmax,ss of Candesartan
2 Not yet recruiting Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);   Drug: Candesartan Cilexetil;   Drug: Candesartan matching placebo;   Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo
Outcome Measures: Change in mean seated systolic blood pressure (MSSBP);   Change in mean seated diastolic blood pressure (MSDBP);   Blood pressure Response Rate;   Blood pressure Control Rate;   Mean change in systolic blood pressure and diastolic blood pressure in ambulatory blood pressure monitoring over 24 hours;   Number of participants with adverse events as a measure of safety and tolerability
3 Recruiting The Potential of Candesartan to Retard the Progression of Aortic Stenosis
Condition: Aortic Valve Stenosis
Interventions: Drug: candesartan;   Drug: placebo
Outcome Measures: The degree of inflammation in stenotic aortic valves;   The degree of calcification, lipid accumulation, and fibrosis in stenotic aortic valves
4 Recruiting A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: Amlodipine 5mg;   Drug: Amlodipine 10mg;   Drug: Candesartan Cilexetil 8mg;   Drug: Candesartan cilexetil 16mg
Outcome Measures: Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline;   Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8;   Change in siDBP at week 4;   Proportion of patients achieving ΔsiDBP > 10 mmHg and ΔsiSBP < 20 mmHg after 8 weeks;   Proportion of patients achieving siDBP < 90 mmHg and siSBP < 120 mmHg after 8 weeks
5 Not yet recruiting CAndesartan vs LIsinopril Effects on the BRain
Conditions: Hypertension;   Mild Cognitive Impairment
Interventions: Drug: Candesartan;   Drug: Lisinopril
Outcome Measures: Executive function (EXAMINER score);   Perfusion and Vasoreactivity (VR);   rs-fMRI
6 Recruiting RAS Quantification in Patients With Aliskiren or Candesartan
Conditions: Hypertension;   Chronic Kidney Disease;   Proteinuria
Interventions: Other: RAS blockade discontinuation;   Drug: Aliskiren;   Drug: Candesartan
Outcome Measures: Mass spectrometry RAS peptide quantification;   Blood pressure;   Proteinuria
7 Recruiting To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
Conditions: Hypertension;   Congestive Heart Failure
Interventions: Drug: Candemore tablet;   Drug: Atacand tablet
Outcome Measures: Mean sitting Systolic Blood Pressure;   Mean Sitting Diastolic Blood Pressure;   echocardiography;   Blood Creatinine and Potssium level;   NYHA class
8 Unknown  Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity
Condition: Breast Cancer
Interventions: Drug: AT1 blocker candesartan;   Drug: Placebo
Outcome Measure: The occurrence of cardiotoxicity, defined as a decline in LVEF (MUGA) of more than 15% or a decrease of less than 15% to an absolute value below 45%.
9 Recruiting Candesartan as a Treatment for Cocaine Dependence
Condition: Cocaine Dependence
Intervention: Drug: Candesartan cilexetil
Outcome Measures: Urine toxicology for cocaine;   Retention;   Adverse Events
10 Recruiting An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Conditions: Methamphetamine Dependence;   Methamphetamine Abuse;   Substance Abuse
Interventions: Drug: Perindopril;   Drug: Placebo;   Drug: Candesartan
Outcome Measures: The dose-dependent effects of an ace inhibitor or an angiotensin receptor blocker on MA- and cue-induced craving and on the reinforcing effects of MA indexed by MA self-administration.;   The effects of an ace inhibitor or an angiotensin receptor blocker on subjective measures.
11 Not yet recruiting CKD-330 Drug-Drug Interaction Study (Amlodipine)
Condition: Hypertension
Interventions: Drug: Amlodipine 10mg;   Drug: Amlodipine 10mg/Candesartan 32mg
Outcome Measures: AUCτ,ss of Amlodipine;   Cmax,ss of Amlodipine;   Tmax,ss of Amlodipine
12 Unknown  CCB Safety Study in Treatment of Hypertension of ADPKD
Condition: Kidney, Polycystic, Autosomal Dominant
Interventions: Drug: Candesartan;   Drug: Candesartan and Cilnidipine;   Drug: Candesartan plus non-CCB agents
Outcome Measures: Kidney Volume measured by MRI.;   Serum creatinine, hemodialysis, cardiovascular events and central nervous vascular events
13 Unknown  Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine
Conditions: HIV Infections;   Hypertension
Interventions: Drug: candesartan;   Drug: lercanidipine
Outcome Measures: morpho-functional left ventricle characteristics;   metabolic profile;   systolic and diastolic blood pressure
14 Unknown  Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
Condition: Essential Hypertension
Interventions: Drug: Imidapril;   Drug: Candesartan
Outcome Measures: PAI-1 level and t-PA activity time course changes;   t-PA activity at the desmopressin test;   Insulin sensitivity state through euglycemic hyperinsulinemic clamp method;   Blood pressure changes
15 Unknown  Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
Conditions: Kidney Failure, Chronic;   Cardiovascular Diseases
Interventions: Drug: Candesartan and enalapril;   Drug: candesartan and enalapril
Outcome Measures: pulse wave velocity (aortic and brachial);   augmentation index;   blood pressure (brachial and aortic);   buckbergs index;   time to reflection;   pulse pressure;   change in glomerular filtration rate (GFR);   blood parameters
16 Unknown  Effectiveness of Candesartan and Telmisartan on Morning Hypertension in Japanese Obese Patients
Condition: Hypertension
Interventions: Drug: Candesartan;   Drug: Telmisartan
Outcome Measures: Home blood pressure in the early morning;   Home blood pressure at bedtime;   M/E ratio;   Casual blood pressure;   Body fat percentage;   Body weight;   Height;   BMI;   Blood potassium;   Total cholesterol;   HDL cholesterol;   LDL cholesterol;   Triglyceride;   Blood glucose;   IRI;   HbAlc*;   HOMA-IR;   Urinary trace albumin;   Creatinine
17 Recruiting Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression
Conditions: Depression;   Hypertension
Interventions: Drug: Sertraline;   Drug: Candesartan
Outcome Measures: MRI Arterial Spin Labeling;   Montgomery Asberg Depression Rating Scale (MADRS);   Quick Inventory of Depressive Symptoms, Self-Rated (QIDS-SR16);   Montgomery-Asberg Depression Rating Scale
18 Recruiting Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy
Conditions: Breast Cancer;   Heart Failure
Interventions: Drug: Metoprolol;   Drug: Placebo;   Drug: Candesartan
Outcome Measures: Change in left ventricular ejection fraction, as assessed by cardiac MRI;   Change in contrast enhancement by MRI;   Change in left 2D global strain, as assessed by echocardiography;   Incidence of clinical of heart failure or objective left ventricular dysfunction;   Change in biochemical markers of cardiac injury, i.e. hs-cTnT;   Change in left ventricular diastolic function, as assessed by echocardiography;   Change in biochemical markers of cardiac function, i.e. NT-proBNP;   Change in contrast enhancement, as assessed by cardiac MRI
19 Unknown  G-Protein-Coupled Receptor Kinase 4 Polymorphisms and Blood Pressure and Response to Candesartan Among Southwestern Han Chinese With Essential Hypertension
Condition: Mild to Moderate Essential Hypertension
Intervention:
Outcome Measure:
20 Recruiting Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Condition: "Cardiorenal Syndrome (CRS)"
Interventions: Drug: Candesartan;   Drug: Placebo
Outcome Measures: Change in Glomerular Filtration Rate (mL/min/1.73 m2);   change in urinary Sodium excretion

These studies may lead to new treatments and are adding insight into Amias etiology and treatment.

A major focus of Amias research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Amias